Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

19 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-08-31

Study Completion Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to investigate patient characteristics of intermediate stage hepatocellular carcinoma patients treated with Nexavar and their distribution to different treatment groups as well as determining efficacy and safety parameters.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

NCT00492752

Carcinoma, Hepatocellular

COMPLETED PHASE3

A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

NCT00105443

Carcinoma, Hepatocellular

COMPLETED PHASE3

A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma

NCT00044512

Carcinoma, Hepatocellular

COMPLETED PHASE2

INSIGHT - Post Marketing Surveillance

NCT00792350

Carcinoma, Hepatocellular

COMPLETED

Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy

NCT01539681

Hepatocellular Carcinoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Hepatocellular

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Sorafenib (Nexavar, BAY43-9006)

Intervention Type DRUG

Patients will be followed-up from start of Nexavar therapy until death or drop out due to any reason or end of study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sorafenib (Nexavar, BAY43-9006)

Patients will be followed-up from start of Nexavar therapy until death or drop out due to any reason or end of study

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a diagnosis of unresectable intermediate stage hepatocellular carcinoma (BCLC-B) for whom the decision has been taken by the investigator to prescribe Nexavar (the BCLC intermediate stage (BCLC-B) consists of Child-Pugh A and B patients with large/multifocal HCC who do not have cancer related symptoms, macrovascular invasion or extrahepatic spread).